Literature DB >> 18313995

Determination of oseltamivir carboxylic acid in human serum by solid phase extraction and high performance liquid chromatography with UV detection.

Gholamreza Bahrami1, Bahareh Mohammadi, Amir Kiani.   

Abstract

This study was aimed at developing a fast and sensitive method for determination of oseltamivir carboxylic acid (OCA), the active moiety of anti-influenza agent, oseltamivir phosphate, in human serum by high performance liquid chromatography and UV detection. The analyte and an internal standard (vanillin) were extracted from human serum by a solid phase extraction (SPE) procedure. Chromatographic separation was achieved using a reverse phase C18 column with a mobile phase consisting of 0.05M phosphate buffer containing triethylamine (1mL/L; pH 3.0) and acetonitrile (70:30, v/v). The detection wavelength was set at 215nm. The average recoveries of the drug and internal standard were 98 and 85%, respectively. The calibration curve was linear over a concentration range of 15-6400ng/mL of OCA in human serum. The lower limits of detection and quantification were 5 and 15ng/mL, respectively. The coefficient variation values of both inter- and intra-day analysis were less than 12% whereas the percentage error was less than 4.5. The stability of the drug at the serum samples maintained at -40 degrees C for 60 days was found to be 100% from the initial value and no interferences were found from either endogenous components in serum or commonly co-administrated antiviral drugs. The validated method was applied to a randomized cross-over bioequivalence study of two different oseltamivir phosphate preparations in 24 healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313995     DOI: 10.1016/j.jchromb.2008.01.048

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Simple and sensitive spectrofluorimetric method for the determination of oseltamivir phosphate in capsules through derivatization with fluorescamine.

Authors:  Zeynep Aydoğmuş
Journal:  J Fluoresc       Date:  2009-01-28       Impact factor: 2.217

3.  Chemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant rats.

Authors:  Chia-Chun Lin; Jiin-Cherng Yen; Yu-Tse Wu; Lie-Chwen Lin; Tung-Hu Tsai
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

4.  Simultaneous quantification of prodrug oseltamivir and its metabolite oseltamivir carboxylate in human plasma by LC-MS/MS to support a bioequivalence study.

Authors:  Ajay Gupta; Swati Guttikar; Pranav S Shrivastav; Mallika Sanyal
Journal:  J Pharm Anal       Date:  2012-12-06

5.  Innovated formulation of oseltamivir powder for suspension with stability study after reconstitution using a developed ion-pair reversed phase high-performance liquid chromatography method.

Authors:  Kahtan Jassim Hasson
Journal:  J Adv Pharm Technol Res       Date:  2022-07-05

6.  Kinetic Study of the Alkaline Degradation of Oseltamivir Phosphate and Valacyclovir Hydrochloride using Validated Stability Indicating HPLC.

Authors:  Ramzia I Al-Bagary; Asmaa A El-Zaher; Fahima A Morsy; Mai M Fouad
Journal:  Anal Chem Insights       Date:  2014-05-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.